Blue Owl Capital Holdings LP Purchases New Stake in ImageneBio, Inc. $IMA

Key Points

• Blue Owl Capital acquired 540,924 shares of ImageneBio (~$4.41M) in Q3, making IMA its 22nd-largest holding (about 1.4% of Blue Owl's portfolio) and leaving Blue Owl with roughly 13.49% ownership of the company.
• ImageneBio trades around $5.84 with a market capitalization of $65.29 million, a negative P/E, and a 1‑year range of $5.70–$18.12 (50-day $6.81; 200-day $7.86).
• Analysts have recently downgraded the stock (Wall Street Zen to "strong sell", Wedbush to "underperform"), though the MarketBeat consensus remains a "Hold" with a price target of $26.50; Director Joseph P. Slattery also bought 16,000 shares at $5.99 and insiders own about 5.94%.

Blue Owl Capital Holdings LP acquired a new position in shares of ImageneBio, Inc. (NASDAQ:IMA - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 540,924 shares of the company's stock, valued at approximately $4,409,000. ImageneBio comprises approximately 1.4% of Blue Owl Capital Holdings LP's holdings, making the stock its 22nd largest position. Blue Owl Capital Holdings LP owned approximately 13.49% of ImageneBio as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its holdings in shares of ImageneBio by 62.4% during the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company's stock valued at $98,000 after buying an additional 29,369 shares during the last quarter. Aldebaran Capital LLC bought a new stake in shares of ImageneBio during the third quarter worth about $159,000. BML Capital Management LLC acquired a new stake in shares of ImageneBio in the 3rd quarter worth about $1,487,000. Finally, Vanguard Group Inc. acquired a new stake in shares of ImageneBio in the 3rd quarter worth about $1,902,000. Institutional investors and hedge funds own 75.00% of the company's stock.

ImageneBio Price Performance

IMA opened at $5.84 on Friday. The company has a market capitalization of $65.29 million, a price-to-earnings ratio of -0.72 and a beta of 0.44. The firm's fifty day moving average price is $6.81 and its two-hundred day moving average price is $7.86. ImageneBio, Inc. has a 1 year low of $5.70 and a 1 year high of $18.12.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wall Street Zen downgraded ImageneBio from a "hold" rating to a "strong sell" rating in a research note on Saturday, November 15th. Wedbush downgraded ImageneBio from a "neutral" rating to an "underperform" rating in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $26.50.

Insider Activity at ImageneBio

In other news, Director Joseph P. Slattery purchased 16,000 shares of the company's stock in a transaction that occurred on Wednesday, December 24th. The shares were bought at an average cost of $5.99 per share, with a total value of $95,840.00. Following the completion of the transaction, the director directly owned 16,000 shares of the company's stock, valued at approximately $95,840. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.94% of the stock is currently owned by corporate insiders.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.

Want to see what other hedge funds are holding IMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImageneBio, Inc. (NASDAQ:IMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.